STOCK TITAN

The Lockwood Group Announces Strategic Investment from Ares Private Equity Group

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Positive)
Tags
Rhea-AI Summary

The Lockwood Group announced a strategic investment from Ares Management Corporation's Private Equity Group on October 12, 2021. While the investment terms remain undisclosed, Lockwood's CEO, Matthew Schecter, expressed enthusiasm for Ares' resources to enhance growth, focusing on expanding capabilities and client service. Ares partner Kevin Ryan highlighted Lockwood's position to capitalize on market opportunities in life sciences. Lockwood, recognized for its scientific expertise and workplace culture, continues to support pharmaceutical and biotech clients with targeted communication strategies.

Positive
  • Strategic investment from Ares Management to support growth.
  • Lockwood's strong reputation as a leader in medical communications.
  • Emphasis on expanding capabilities and client services.
Negative
  • None.

STAMFORD, Conn., Oct. 12, 2021 /PRNewswire/ -- The Lockwood Group ("Lockwood"), an industry leader in scientific-based medical communications for the pharmaceutical, biotech, and medical device industries, announced today a strategic investment made by a fund managed by the Private Equity Group of Ares Management Corporation (NYSE: ARES) ("Ares"). Terms of the investment were undisclosed.

"We are excited to find in Ares a partner that appreciates our differentiated culture, deep scientific expertise, and close-knit community of teammates," said Matthew Schecter, President and Chief Executive Officer of Lockwood. "Ares brings a wealth of resources and experience that we believe will help Lockwood accelerate growth by investing in our people, customers, and capabilities. Our team is energized by the opportunity ahead of us."

Lockwood's executive management team, led by Schecter and Chief Operating Officer, Christine Hinkle, will continue to guide the company with an emphasis on growth, capability expansion, and providing leading scientific thinking to our life science clients. As a 5-time Inc. Magazine 5000 Fastest-Growing Private Company in America and a 7-time Best Places to Work in Connecticut winner, Lockwood will maintain its commitment to delivering exceptional client service, the highest-caliber scientific expertise, and a supportive team culture.

"As an industry leader in helping pharmaceutical and biotech customers bring innovative treatment options to market, with the ultimate goal of serving patients, we believe Lockwood is well-positioned to benefit from a number of secular tailwinds," said Kevin Ryan, Partner in the Ares Private Equity Group. "We are thrilled to support Matt, Christine and the entire Lockwood leadership team as they seek to execute against the Company's numerous organic and inorganic growth opportunities."

Houlihan Lokey served as the exclusive financial advisor to The Lockwood Group.

About The Lockwood Group

Founded in 2007 and headquartered in Stamford, Connecticut, Lockwood communicates clinical and therapeutic advances to every type of medical expert, healthcare practitioner, and decision maker. For the ultimate benefit of patients, Lockwood helps clients advance their objectives in a world of new regulations, business models, payment approaches, technologies, roles, and work practices. Lockwood teams are organized around the specific needs of each client. With extensive experience in oncology, rare diseases, and all major therapeutic areas, along with highly specialized knowledge in biologics, devices, and diagnostics, Lockwood can quickly deploy the right scientific, business, and communications experts to address the challenges at hand.

About Ares Management Corporation

Ares Management Corporation (NYSE: ARES) is a leading global alternative investment manager offering clients complementary primary and secondary investment solutions across the credit, private equity, real estate, and infrastructure asset classes. We seek to provide flexible capital to support businesses and create value for our stakeholders and within our communities. By collaborating across our investment groups, we aim to generate consistent and attractive investment returns throughout market cycles. As of June 30, 2021, including the acquisition of Black Creek Group, which closed July 1, 2021, Ares Management Corporation's global platform had approximately $262 billion of assets under management, with approximately 2000 employees operating across North America, Europe, Asia Pacific, and the Middle East. For more information, please visit www.aresmgmt.com. Follow Ares on Twitter @Ares_Management.

Cision View original content:https://www.prnewswire.com/news-releases/the-lockwood-group-announces-strategic-investment-from-ares-private-equity-group-301398595.html

SOURCE The Lockwood Group

FAQ

What investment did Ares make in Lockwood Group?

Ares Management's Private Equity Group made a strategic investment in The Lockwood Group, though the terms are undisclosed.

When was the Lockwood Group investment announced?

The investment by Ares Management was announced on October 12, 2021.

What is the significance of Ares' investment in Lockwood?

Ares' investment is expected to enhance Lockwood's growth and capabilities in medical communications.

Who is the CEO of Lockwood Group?

Matthew Schecter is the President and CEO of The Lockwood Group.

What industry does Lockwood Group operate in?

The Lockwood Group operates in scientific-based medical communications for the pharmaceutical, biotech, and medical device industries.

Ares Management Corporation

NYSE:ARES

ARES Rankings

ARES Latest News

ARES Stock Data

33.89B
198.39M
13.8%
83.18%
1.87%
Asset Management
Investment Advice
Link
United States of America
LOS ANGELES